Predictions
Drägerwerk AG & Co. KGaA VZO
Start price
Target price
Perf. (%)
€61.80
08.03.21
08.03.21
-
08.03.22
08.03.22
-21.91%
09.03.22
09.03.22
Drägerwerk AG & Co. KGaA ST
Start price
Target price
Perf. (%)
€61.80
08.03.21
08.03.21
-
08.03.22
08.03.22
-26.29%
09.03.22
09.03.22
Fresenius Medical Care AG & Co KGaA ST
Start price
Target price
Perf. (%)
€57.94
01.03.21
01.03.21
-
01.03.22
01.03.22
-2.93%
02.03.22
02.03.22
Vita 34 AG
Start price
Target price
Perf. (%)
€15.55
21.02.21
21.02.21
-
21.02.22
21.02.22
-25.08%
22.02.22
22.02.22
Very Future proof/growth oriented business model
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€36.24
01.02.21
01.02.21
€40.00
01.02.22
01.02.22
1.56%
01.02.22
01.02.22
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€38.44
27.01.21
27.01.21
€45.00
27.01.22
27.01.22
-4.29%
28.01.22
28.01.22
Could be worthwhile Investment >10% per year
Drägerwerk AG & Co. KGaA ST
Start price
Target price
Perf. (%)
€67.80
23.01.21
23.01.21
€88.00
23.01.22
23.01.22
-26.99%
24.01.22
24.01.22
Fair valuation
Top 10 in its market
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Drägerwerk AG & Co. KGaA VZO
Start price
Target price
Perf. (%)
€71.80
23.01.21
23.01.21
€88.00
23.01.22
23.01.22
-30.36%
24.01.22
24.01.22
Market Leader or Top 3
Well known brand
Very Future proof/growth oriented business model
Revenue growth > 30% per year expected
Bio-Gate AG
Start price
Target price
Perf. (%)
€4.14
09.01.22
09.01.22
-
09.01.23
09.01.23
-5.80%
23.01.22
23.01.22
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Eckert & Ziegler Strahlen- und Medizintechnik AG
Start price
Target price
Perf. (%)
€123.30
17.08.21
17.08.21
-
17.08.22
17.08.22
-27.01%
12.01.22
12.01.22
Mediclin AG
Start price
Target price
Perf. (%)
€4.36
10.01.21
10.01.21
€6.00
10.01.22
10.01.22
-15.14%
11.01.22
11.01.22
EBIT growth >5% per year expected
positive Cash Flow expected
Top 10 in its market
Future proof or reliable business model
Stratec SE
Start price
Target price
Perf. (%)
€122.40
30.12.20
30.12.20
€128.00
30.12.21
30.12.21
12.75%
31.12.21
31.12.21
Could be worthwhile Investment >10% per year
Drägerwerk AG & Co. KGaA VZO
Start price
Target price
Perf. (%)
€76.10
09.07.21
09.07.21
-
09.07.22
09.07.22
-25.49%
05.12.21
05.12.21
Bio-Gate AG
Start price
Target price
Perf. (%)
€5.90
04.11.20
04.11.20
-
04.11.21
04.11.21
-32.20%
05.11.21
05.11.21
Growths faster than the competition
Few uniques
Dependend from some customers or products
Probably not worthwhile Investment
M1 Kliniken AG
Start price
Target price
Perf. (%)
€9.44
06.08.20
06.08.20
€12.00
04.11.21
04.11.21
-12.08%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Capable Management
Small cyclical dependencies
Gerresheimer AG
Start price
Target price
Perf. (%)
€59.40
01.04.20
01.04.20
€100.00
04.11.21
04.11.21
39.81%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€42.80
02.03.20
02.03.20
-
04.11.21
04.11.21
-8.24%
05.11.21
05.11.21
Eckert & Ziegler Strahlen- und Medizintechnik AG
Start price
Target price
Perf. (%)
€38.20
12.09.19
12.09.19
€37.50
04.11.21
04.11.21
255.24%
05.11.21
05.11.21
Carl Zeiss Meditec AG
Start price
Target price
Perf. (%)
€101.30
10.08.19
10.08.19
€169.00
04.11.21
04.11.21
83.17%
05.11.21
05.11.21
Carl Zeiss Meditec AG
Start price
Target price
Perf. (%)
€87.10
05.05.19
05.05.19
€200.00
04.11.21
04.11.21
113.03%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Carl Zeiss Meditec AG
Start price
Target price
Perf. (%)
€67.50
27.07.18
27.07.18
€110.00
04.11.21
04.11.21
174.89%
05.11.21
05.11.21
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€34.41
09.11.20
09.11.20
€40.00
09.11.21
09.11.21
18.27%
02.11.21
02.11.21
Could be very worthwhile Investment >20% year
Market Leader or Top 3
Revenue growth >5% per year expected
EBIT growth >5% per year expected